Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT01822496 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2019-08-05 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MET in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-07-27Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Osimertinib (NCT04487080)
- 2020-07-15Phase 3 first posted: Hoffmann-La Roche, Cabozantinib + Atezolizumab (NCT04471428)
- 2020-06-11Phase 3 first posted: Novartis Pharmaceuticals, Capmatinib + Docetaxel (NCT04427072)
- 2019-07-11Results posted on the registry: Hoffmann-La Roche, Alectinib + Crizotinib (NCT02838420)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision